Bpifrance

Chipiron is a developer of innovative portable MRI machines that utilize advanced quantum detectors to generate three-dimensional anatomical images. By operating at ultra-low magnetic fields, these machines are designed to be lightweight and efficient, significantly reducing costs compared to traditional MRI technologies. The company's focus on employing quantum sensors enhances the capability of these portable devices for disease detection, diagnosis, and treatment monitoring, particularly for brain-related conditions. This approach aims to empower healthcare institutions to improve patient outcomes and decrease the fatality rates associated with neurological diseases.

Poppins is a developer of digital therapeutic technology aimed at enhancing cognitive function in children with learning disorders. The company creates interactive musical games that integrate neurologic music therapy methods to address conditions such as dyslexia, dysphasia, and dyspraxia. These games focus on improving essential skills like concentration, motor skills, and memory through engaging activities that can be performed at home. By leveraging data science and advanced technologies, Poppins interprets learning, language, and motor performance to generate a cognitive score, facilitating personalized treatment plans. The company's mission is to provide accessible digital solutions for children facing learning challenges, ultimately aiming to improve their reading abilities and memory retention while supporting speech therapy.

H'ability specializes in providing immersive virtual reality (VR) therapeutic exercises that complement traditional rehabilitation methods. The company offers a wireless VR headset with customizable exercises targeting motor skills, balance, and cognitive functions. Their platform features real-time session personalization, detailed progress tracking with data analytics, and compatibility with additional rehabilitation tools. This enables healthcare professionals to deliver personalized, engaging, and efficient therapy sessions in clinical settings or at patients' homes, catering to various medical conditions.

Parallel builds AI agents that streamline healthcare admin workflows, seamlessly integrated to unlock efficiency at scale.

Fizimed SAS, founded in 2017 and based in Strasbourg, France, specializes in manufacturing a perineal device designed to address urinary incontinence in women through pelvic floor reeducation. The company's flagship product, EMY, is a perineal probe that connects to a mobile app, allowing users to engage in personalized exercises for strengthening pelvic floor muscles. EMY not only captures real-time muscle contractions but also incorporates interactive elements, such as games, to motivate users during their five-minute workouts. Fizimed emphasizes user-friendliness and safety in its product design, aiming to empower women in managing their pelvic health at home. Additionally, the company actively seeks to eliminate the stigma surrounding urinary incontinence, fostering a supportive community on social media where women can share experiences and innovations related to this common health issue. Through its combination of medical efficacy and engaging technology, Fizimed aims to provide women with the tools they need to regain control over their pelvic health in a discreet and enjoyable manner.

MSInsight is a bioinformatics startup that specializes in developing diagnostic and treatment response prediction solutions for cancers with Microsatellite Instability (MSI). The company's core offering revolves around identifying and analyzing diagnostic and prognostic biomarkers of treatment response in MSI tumors. By leveraging next-generation sequencing data, MSInsight's platform provides actionable insights on MSI status, a critical biomarker for cancer treatment, enabling healthcare professionals to make informed decisions about patient care, particularly in relation to immunotherapy options, and ultimately improve patient outcomes.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

MB Therapeutics is a pharmaceutical company that specializes in patient-centric solutions for the development and production of tailored medicines. It operates a system that enables the creation of customized medications, including the combination of multiple active ingredients into a single unit, and offers evaluation services. The company's focus is on enhancing treatment precision and improving patient adherence through the customization of medication dosage and forms.

EG 427 is a French biotechnology company that specializes in pinpoint gene therapy, aimed at treating disorders related to spinal cord injuries. The company utilizes HSV-1-based vectors, leveraging the natural characteristics of the Herpes Simplex Virus 1 to establish lifelong latency in peripheral neurons. This innovative approach allows for targeted and sustained expression of therapeutic genes, providing a potential cure for severe, chronic, and localized conditions, such as neurogenic bladder disorders resulting from spinal cord injuries. By focusing on this advanced gene therapy technique, EG 427 seeks to improve treatment outcomes for patients suffering from these debilitating conditions.

Ochy is a mobile application that leverages video technology and artificial intelligence to deliver lab-quality analysis of running techniques directly to users' smartphones. The platform is designed to help runners assess their biomechanics, identify weaknesses, and receive tailored exercise plans aimed at enhancing performance and preventing injuries. By analyzing users' movements, Ochy provides insights that can support athletes, coaches, and medical professionals alike. Coaches can utilize the app to better understand their athletes and optimize training programs, while runners without access to coaching can independently evaluate their technique. Additionally, medical professionals can use the application's analysis to assess patient techniques and guide rehabilitation efforts effectively.

Coave Therapeutics specializes in developing gene therapies aimed at treating rare ocular and central nervous system diseases. The company focuses on innovative solutions for rare retinal disorders, utilizing a recombinant adeno-associated virus that substitutes the viral DNA with a functional copy of the PDE6B gene. This therapeutic approach involves injecting the corrected version of the protein between the photoreceptors and the retinal pigment epithelium, providing patients with effective treatment options for various eye conditions.

Vetbiolix is a veterinary biotechnology company dedicated to developing innovative therapeutic solutions for dogs and cats. The company focuses on creating first-in-class drug candidates aimed at treating and preventing diseases that affect pets, particularly in areas such as periodontitis, osteoarthritis, and gut motility disorders. By emphasizing clinical development, Vetbiolix strives to offer effective treatments for common health issues in pets, ultimately enhancing their quality of life.

Orakl Oncology specializes in expediting cancer drug discovery by employing advanced biology and AI-driven analysis. It maintains a unique collection of patient tumor avatars, integrating biological and clinical data, to create realistic tumor models that mimic real-life drug responses. By mining multi-modal experimental data and combining it with deep patient data, Orakl enables oncology companies to identify relevant targets and develop more effective treatments at an accelerated pace.

Biolevate is an AI-driven company focused on enhancing healthcare research and patient care. It offers IT consulting services, employing advanced AI algorithms to streamline research workflows. The company's platform automates tasks such as document generation and literature monitoring, intelligently filtering vast datasets to provide relevant, actionable scientific information. It offers customizable search options and insightful data visualizations, empowering clients to make informed decisions and accelerate scientific breakthroughs, ultimately improving patient care.

Theremia is a health technology company that leverages artificial intelligence to transform drug development, with a focus on neurological disorders. It employs advanced machine learning to optimize drug compounds for specific demographic groups, enhancing treatment effectiveness and reducing adverse effects.

Doado is a health technology company that specializes in developing mobile applications for back health management. Its primary product is an e-health application designed to guide users step by step in improving their back health and preventing Musculoskeletal Disorders. The application offers personalized video programs, expert advice from physiotherapists and doctors, and AI-driven progress tracking, enabling individuals and companies to maintain an active lifestyle and reduce the risk of chronic back pain.

Skezi is an e-cohort startup that believes that valuing the voices of patients, caregivers, families, and carers would enhance future health. SKEZI offers solutions adapted to all sectors of sensitive data through its subscription offer to its SaaS platforms.

Vaxinano is a biotechnology company focused on the preclinical and pharmaceutical development of vaccines and drug delivery systems for both humans and animals. Established in 2016, Vaxinano builds on 25 years of research and clinical trials related to vaccines, utilizing the patented technology of Pr Didier Betbeder. The company specializes in creating safe-by-design nanoparticles that adhere to green chemistry principles, which support the development of prophylactic and therapeutic vaccines for infectious diseases. Additionally, Vaxinano aids medical researchers in formulating drugs that activate biomolecules, proteins, and antigens, thereby facilitating innovative approaches to combat untreated viral, bacterial, and parasitic diseases.

Vetbiolix is a veterinary biotechnology company dedicated to developing innovative therapeutic solutions for dogs and cats. The company focuses on creating first-in-class drug candidates aimed at treating and preventing diseases that affect pets, particularly in areas such as periodontitis, osteoarthritis, and gut motility disorders. By emphasizing clinical development, Vetbiolix strives to offer effective treatments for common health issues in pets, ultimately enhancing their quality of life.

HEPTA Medical is a medical technology company focused on developing a microwave ablation platform for the treatment of early lung cancer. The company's innovative solution includes a microwave ablation catheter equipped with a proprietary temperature sensor, which allows healthcare professionals to monitor and control the ablation volume in real-time. This technology aims to provide a minimally invasive, nonsurgical treatment option, enhancing the efficiency and safety of cancer ablation procedures. By enabling precise control over the size of the lesion being treated, HEPTA Medical seeks to improve patient outcomes in cancer care.

Archeon is focused on creating innovative solutions for the monitoring, diagnosis, and treatment of critically ill patients in prehospital care. The company develops artificial intelligence-based technologies aimed at enhancing ventilation quality in emergency medical services. Its products are designed to be practical, user-friendly, and intuitive for emergency caregivers, providing real-time feedback on the quality of ventilation administered to patients. This approach aims to improve patient outcomes and support medical professionals in high-pressure situations.

UroMems is a company dedicated to addressing specific clinical needs related to patient care, particularly in the area of urology. It develops implantable medical devices aimed at enhancing existing surgical treatments, thereby improving patient outcomes and reducing side effects. By focusing on innovative solutions, UroMems seeks to ensure that more patients can access effective treatments quickly, ultimately aiming to enhance their quality of life. The company is committed to the design, development, and commercialization of these active implantable devices, which reflect a deep understanding of the challenges faced by patients.

Starkage Therapeutics is a discovery-stage biotechnology company focused on improving the quality of life for patients suffering from various health conditions. The company is developing a platform that targets the depletion of senescent cells, which are linked to age-related diseases, through a combination of immunotherapy and cancer treatment approaches. Starkage Therapeutics aims to address unmet medical needs in areas such as idiopathic pulmonary fibrosis, neurodegenerative diseases, and metabolic dysfunction or hepatic fibrosis. Through its innovative research and therapeutic strategies, the company seeks to enhance patient health and treatment outcomes.

Biodol Therapeutics SAS, founded in 2015 and located in Clapiers, France, focuses on developing innovative treatments for chronic pain. The company has identified the receptor tyrosine kinase FLT3 as a critical factor in triggering and sustaining chronic neuropathic pain. Through its proprietary approach, Biodol Therapeutics develops extracellular inhibitors of the FLT3 receptor, which aim to inhibit ligand binding and thereby alleviate conditions such as allodynia, pain hypersensitivity, and spontaneous pain without disrupting normal nervous system function. Additionally, research partnerships have indicated that inhibiting FLT3 may enhance the efficacy of opioids, potentially reducing their associated risks, including addiction. This innovative work positions Biodol Therapeutics as a significant player in addressing chronic pain and contributing to solutions for the opioid crisis.

MaaT Pharma is a clinical-stage biotechnology company based in Lyon, France, founded in 2014. It specializes in developing therapies aimed at treating diseases associated with gut microbiota imbalance, particularly in the context of cancer and Graft-versus-Host Disease, a complication related to stem cell transplantation. The company has made significant advancements in its research, achieving proof of concept in patients with acute myeloid leukemia. MaaT Pharma employs a comprehensive approach to restore microbiome symbiosis, which has implications for enhancing survival outcomes in life-threatening conditions. Additionally, it has developed a proprietary platform called GutPrint®, which is instrumental in evaluating drug candidates and identifying biomarkers for microbiome-related diseases, thereby supporting the expansion of its therapeutic pipeline, including improvements in immunotherapy for solid tumors.

Hephaistos Pharma is a biotechnology company focused on advancing oncology treatments through innovative immunotherapy solutions. The firm develops a platform that utilizes active and non-specific immuno-stimulants to enhance the effectiveness of existing antibodies by transforming cold tumors into hot targets, which can significantly improve patient outcomes. This approach aims to address unmet medical needs in cancer treatment, enabling patients to tackle previously incurable cancers. Hephaistos Pharma is dedicated to elevating immunotherapy efficiency by stimulating immune responses, thereby offering new hope in the fight against cancer. Interested parties can access more information through an online inquiry form available on the company's website.

May Health specializes in developing innovative solutions for infertility related to Polycystic Ovary Syndrome (PCOS). The company offers a minimally invasive procedure aimed at restoring ovulation in women with PCOS, providing a more natural approach to pregnancy. This one-time treatment is performed transvaginally under ultrasound guidance, eliminating the need for general anesthesia. The procedure is designed to assist the body's natural ovulation process and can be conducted in a clinical setting, similar to techniques used by fertility specialists in in vitro fertilization (IVF). May Health's focus is on delivering effective, durable solutions for patients seeking to conceive while minimizing the medicalization of the pregnancy experience.

Klineo operates a digital platform that simplifies and enhances access to clinical trials for oncology patients and healthcare professionals. The platform offers two user interfaces, one for patients and one for doctors, enabling them to search for and connect with relevant clinical trials, particularly for breast, skin, and lymphoma conditions.

Pixacare is a company that develops a medical imaging application aimed at enhancing wound care management for healthcare professionals. This secure and collaborative platform automates medical photo management and centralizes essential data for monitoring wounds, making it user-friendly on both mobile and desktop devices. The application is a Class I CE-marked digital medical device that integrates seamlessly with existing healthcare infrastructures, including Patient Administration Systems and Electronic Health Records, ensuring interoperability. By transforming any smartphone camera into a secure documentation tool, Pixacare enables home-care staff, surgeons, and dermatologists to monitor and anticipate complications in chronic and post-surgery wounds. This innovation allows healthcare professionals to optimize their activities and save time in visual specialties while ensuring data security through hosting on certified Health Data Hosting servers.

Tribun Health is a company focused on transforming cancer detection through innovative diagnostic imaging software. Its solutions enable diagnostic laboratories and the pharmaceutical and biotech sectors to effectively manage, analyze, and share cellular images. By offering digital microscopy-like analysis along with macroscopic imaging capabilities, Tribun Health enhances the accuracy of diagnostics and scientific evaluations related to patient cells and tissues. The company's technology aims to streamline the workflow in laboratories, facilitating better collaboration and data sharing among healthcare professionals.

SeaBeLife Biotech SAS is a biotechnology company based in Roscoff, France, established in 2019. The company focuses on developing innovative drug candidates aimed at treating acute pathologies, particularly acute liver and renal failure. SeaBeLife's products are derived from a family of patented molecules designed to block regulated necrosis, a type of regulated cell death. By targeting two synergistic pathways involved in various acute and chronic diseases, SeaBeLife aims to establish a new standard of care for patients with significant unmet medical needs. Through its research and development efforts, the company seeks to enhance patient outcomes and reduce complications associated with serious health conditions.

Chipiron is a developer of innovative portable MRI machines that utilize advanced quantum detectors to generate three-dimensional anatomical images. By operating at ultra-low magnetic fields, these machines are designed to be lightweight and efficient, significantly reducing costs compared to traditional MRI technologies. The company's focus on employing quantum sensors enhances the capability of these portable devices for disease detection, diagnosis, and treatment monitoring, particularly for brain-related conditions. This approach aims to empower healthcare institutions to improve patient outcomes and decrease the fatality rates associated with neurological diseases.

ABIONYX Pharma SA is a French biopharmaceutical company established in 2005, currently based in Labege. It specializes in the discovery and development of therapies targeting high-density lipoprotein (HDL) for treating cardiovascular and metabolic diseases. The company's primary focus is on developing HDL mimetics to rapidly regress atherosclerotic plaque in high-risk patients. Its lead product candidate, CER-001, is a Phase II clinical trial asset designed to mimic the properties of pre-beta HDL for treating post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients. Additionally, ABIONYX Pharma has another drug candidate, CER-209, in Phase I trials for metabolic diseases and liver-related conditions such as atherosclerosis and non-alcoholic steato-hepatitis.

HawkCell is a medical research company specializing in advanced magnetic resonance imaging (MRI) solutions for veterinary clinics and preclinical research laboratories. The company utilizes a non-ionizing three-dimensional (3D) imaging approach, employing specialized MRI sensors designed to accommodate various animal morphologies. By adapting human MRI technology for animal diagnostics, HawkCell provides sustainable systems enhanced with artificial intelligence algorithms. This innovation allows veterinary clinics and research labs to obtain precise and insightful imaging, facilitating improved animal healthcare and scientific exploration.

Pixee Medical is a medical technology company based in Chavanod, France, founded in 2017. The company specializes in the manufacturing of computer-assisted surgical solutions that utilize advanced computer vision and artificial intelligence technologies. Pixee Medical produces medical equipment designed to control the positioning of implants during orthopedic surgeries. Its innovative tracking tools enable precise three-dimensional localization of surgical objects, allowing healthcare professionals to perform procedures with millimeter accuracy. By focusing on affordability, Pixee Medical aims to provide effective surgical navigation solutions that address the challenges of the current healthcare environment.

I.Ceram SA is a France-based company that specializes in the design, manufacture, and marketing of alumina bio-ceramic implants for various joints of the human body. Founded in 2005 and headquartered in Limoges, I.Ceram offers a range of implants for the ankle, knee, hip, spine, shoulder, wrist, skull, tibia, and foot, as well as osteosynthesis products. The company operates both domestically and internationally, emphasizing innovation and high-quality materials in its product offerings. I.Ceram is a subsidiary of Investissement Développement.

Ochy is a mobile application that leverages video technology and artificial intelligence to deliver lab-quality analysis of running techniques directly to users' smartphones. The platform is designed to help runners assess their biomechanics, identify weaknesses, and receive tailored exercise plans aimed at enhancing performance and preventing injuries. By analyzing users' movements, Ochy provides insights that can support athletes, coaches, and medical professionals alike. Coaches can utilize the app to better understand their athletes and optimize training programs, while runners without access to coaching can independently evaluate their technique. Additionally, medical professionals can use the application's analysis to assess patient techniques and guide rehabilitation efforts effectively.

Huvy specializes in developing a skin cancer screening application that utilizes artificial intelligence to enhance dermatological treatment pathways. The application aims to identify cancer risks and provide essential medical information in real-time. By facilitating dermatological screening, Huvy's technology enables access to initial diagnostic orientation for populations in areas with limited medical resources. This approach allows for timely care and intervention when there is a suspicion of skin cancer, ultimately improving health outcomes for underserved communities.

Callyope is a technology company that specializes in remote brain health monitoring. It operates a speech-based platform that uses natural language processing and signal processing techniques to analyze patients' speech, aiding caregivers in detecting relapses and making informed care decisions. This enhances the objectivity and responsiveness of brain health monitoring, potentially improving patients' quality of life and reducing re-hospitalization rates.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

Steto Its mission is to create solutions for remote patient monitoring and digital diabetes therapies.

Astraveus is transforming cell and gene therapy (CGT) manufacturing through its Lakhesys™ platform, an innovative cell foundry that leverages deep process optimization and microfluidic bioprocessors. This technology allows for the production of personalized biological therapies with minimal infrastructure requirements, ultimately reducing costs and addressing logistical challenges in the industry. By automating autologous bioproduction, the platform enhances the efficiency of transforming cells into therapeutic agents, enabling healthcare providers to scale the development and manufacturing of CGT solutions. Astraveus aims to improve patient access to these vital therapies while minimizing environmental impact.

Poppins is a developer of digital therapeutic technology aimed at enhancing cognitive function in children with learning disorders. The company creates interactive musical games that integrate neurologic music therapy methods to address conditions such as dyslexia, dysphasia, and dyspraxia. These games focus on improving essential skills like concentration, motor skills, and memory through engaging activities that can be performed at home. By leveraging data science and advanced technologies, Poppins interprets learning, language, and motor performance to generate a cognitive score, facilitating personalized treatment plans. The company's mission is to provide accessible digital solutions for children facing learning challenges, ultimately aiming to improve their reading abilities and memory retention while supporting speech therapy.

BariaTek is a provider of innovative solutions in the field of bariatric surgery. The company focuses on offering minimally invasive treatments that mimic the effects of traditional surgery through the use of advanced endoscopic techniques. By utilizing trans-oral access and implantable devices, BariaTek aims to provide patients with a painless alternative to conventional bariatric procedures. This approach not only enhances patient comfort but also seeks to improve health outcomes by facilitating effective weight loss and disease management.

EverImmune is focused on developing innovative biotherapeutic products aimed at treating cancer patients through microbiome oncology. The company specializes in creating live biotherapeutic products (LBP) that serve as oral adjuvants to enhance anticancer immunotherapies. By leveraging technology to safely boost the immune system and restore sensitivity to immunotherapies, EverImmune seeks to improve the effectiveness of cancer treatments, particularly in cases of primary resistance. The firm plans to conduct well-designed clinical trials to test its lead product, Oncobax®, as part of its commitment to advancing cancer care.

Tribun Health is a company focused on transforming cancer detection through innovative diagnostic imaging software. Its solutions enable diagnostic laboratories and the pharmaceutical and biotech sectors to effectively manage, analyze, and share cellular images. By offering digital microscopy-like analysis along with macroscopic imaging capabilities, Tribun Health enhances the accuracy of diagnostics and scientific evaluations related to patient cells and tissues. The company's technology aims to streamline the workflow in laboratories, facilitating better collaboration and data sharing among healthcare professionals.

Teale is a digital mental health platform that integrates psychology and technology to enhance mental well-being. The platform offers personalized and interactive digital healthcare solutions, enabling individuals to manage their mental health effectively. Teale also conducts collective workshops tailored to specific needs within workplaces, fostering a supportive environment for mental health initiatives. Through its curated network of mental health experts, Teale provides individual support and personalized digital programs, allowing users to monitor and improve their psychological resilience. This approach not only benefits individuals but also contributes to sustainable growth for organizations.

Give smart ears to product. Saas B2B of an embedded AI to detect distress sounds (applied first to telecare companies).

Pollen Robotics designs and develops humanoid service robots that cater to the healthcare, retail, and education sectors. These robots are equipped with advanced robotic arms that enable precise object manipulation, facilitating various tasks. Pollen Robotics emphasizes customization and connectivity in its products, allowing users to adapt the robots for different applications. The technology also incorporates features to convey emotions, which enhances interaction and engagement. This innovative approach allows scientists, artists, and innovators to explore new possibilities, making the potential of robotics accessible to a broader audience.

X-Pressure is a medical device to measure cerebrospinal fluid pressure to better diagnose brain diseases.

SMAIO is a manufacturer of medical devices for spinal pathologies. They provide control over surgical procedures to the spine physician through a range of solutions.

Gleamer is a company specializing in artificial intelligence-based solutions for radiology, focusing on enhancing diagnostic accuracy for medical imaging. By integrating its AI companions into the existing reading environments of radiologists, Gleamer provides an automated second reading that aids in the detection of bone abnormalities, lesions, and other critical details in X-ray images. This technology not only improves efficiency but also helps ensure that all patients receive accurate diagnoses. Currently, Gleamer's solutions are utilized in over 300 institutions across 13 countries, demonstrating its commitment to advancing radiological practices and supporting medical professionals in prioritizing patient care.

Numa Health is a medical bioinformatics company that develops a digital health platform aimed at helping individuals optimize their health and well-being. The platform offers tools that reinterpret blood test results, providing users with insights into their body's functioning. By delivering accessible health information, Numa Health enables individuals to measure, understand, and take action regarding their health, fostering a greater commitment to personal health management.

CorWave is a developer of advanced implanted cardiac support devices aimed at improving the quality of life for patients with heart failure. The company's flagship product, an innovative left ventricular assist device (LVAD), employs a unique undulating disc wave pumping mechanism. This design enhances blood flow by mimicking the natural pulsation of the heart, significantly reducing trauma to blood and minimizing complications associated with clotting and bleeding, which are common with traditional continuous flow pumps. Additionally, CorWave's LVAD is characterized by low power consumption and compact size, making it suitable for complete implantation and integration with a wireless energy transfer system. Through its pioneering technology, CorWave seeks to alleviate the burdens of heart failure and lessen the need for invasive surgical interventions.

Santexpat is a health insurance platform tailored for French expatriates, operating in over 200 countries. Established in 2020 and headquartered in Paris, it provides users with the ability to analyze more than 100 health insurance options and subscribe directly online. The platform displays insurer prices aligned with public rates, ensuring transparency by including all costs without additional fees. Users can manage their insurance premiums directly through the site of their chosen insurer. Additionally, Santexpat offers 24/7 teleconsultations with French-speaking doctors, enhancing access to healthcare for expatriates.

IA Medical transforms raw data into intelligent patient knowledge. Its algorithms help to understand patient data, from diagnosis to follow-up, to support them with its conversational agents but also to set up a hybrid solution of cognitive and behavioral therapies.

Maddie is a healthcare platform that specializes in patient and practice management software specifically designed for physiotherapists. The company provides tools that assist health professionals in managing their practices efficiently. Its offerings include digital diaries, online appointment booking systems, and customizable websites that enhance online visibility. These solutions enable physiotherapists to organize waiting lists, optimize their schedules, and effectively manage incoming requests, thereby improving overall practice management.

Kairos Discovery is a biotechnology company focused on developing innovative targeted cancer therapies. The company aims to create medicinal chemistry solutions that address key cellular mechanisms responsible for the survival and aggressiveness of both solid tumors and hematological cancers. By utilizing a first-in-class approach, Kairos Discovery seeks to provide breakthrough technology in oncology, ultimately improving the lives of cancer patients and their families.

Santé Académie is an online training platform focused on providing continuous medical education to healthcare professionals. Recognizing the evolving roles of caregivers and the rapid obsolescence of medical knowledge, the platform offers high-quality educational videos tailored to the schedules of busy professionals. Each course is divided into short episodes ranging from 5 to 15 minutes, allowing doctors, nurses, pharmacists, and care assistants to learn at their own pace. The courses cover clinical and regulatory topics and are certified by the ANDPC, produced by experts from prestigious institutions. With the aim of enhancing patient care and engagement, Santé Académie has already gained approval from over 20,000 professionals and health institutions, making advanced medical knowledge accessible directly from mobile devices.

Deemea is a developer of a digital medical assistance platform tailored for clinical research and the analysis of real-life data. The company's AI-driven platform assists clinical research operators by streamlining the imaging data journey, enhancing efficiency and reliability. It utilizes artificial intelligence to identify suitable databases, expedites contractual and regulatory processes, and simplifies external model validation. Additionally, Deemea's platform optimizes responses to internal and external requests while valorizing real-world data and clinical studies. Through these capabilities, Deemea supports clients in accelerating the development and deployment of innovative projects that leverage AI tools specific to the valorization of medical data.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapies for advanced liver diseases, including liver fibrosis, cirrhosis, and liver cancer. Established in 2019, Alentis is recognized for its pioneering work in targeting CLDN1+ cancers through the use of anti-CLDN1 antibody-drug conjugates and other therapeutic modalities. The company's research platform incorporates clinically relevant read-outs and single-cell RNA sequencing of patient liver tissues, which aids in understanding and treating fibrotic diseases. Alentis aims to modify and reverse disease progression, ultimately addressing significant health challenges associated with liver-related conditions.

Odimma is a biotech company specializing in precision medicine aimed at developing personalized cancer immunotherapy solutions. The company has created an innovative immunotherapy drug that harnesses a unique platform, integrating three specific immune components designed to work together with the patient's immune system. When administered, this approach aims to induce and enhance immune responses, providing patients with the potential to eliminate tumors while minimizing adverse side effects. Through its focus on personalized treatment strategies, Odimma seeks to improve outcomes for cancer patients by tailoring therapies to individual needs.

Hemerion is a biotechnology company dedicated to developing innovative cancer treatments, specifically targeting glioblastoma, the most prevalent and aggressive primary brain tumor. The company operates a platform that integrates therapeutic services at the intersection of surgery and photonics, utilizing a photosensitizing drug for a drug-device combination therapy. This approach enables healthcare professionals to selectively destroy cancer cells in regions that are difficult to access through traditional surgical methods, all while preserving healthy tissues. Hemerion's focus on advanced treatment options aims to enhance the healthcare industry's ability to combat brain cancer and improve patient outcomes in the fight against glioblastoma.

Kayentis is a global leader in electronic clinical outcome assessment (eCOA) and decentralized clinical trial solutions, dedicated to enhancing data collection processes in clinical trials for the pharmaceutical, biotech, and contract research organization sectors. Founded in 2005, the company has developed expertise in eCOA solutions applicable across all phases of clinical development, addressing over 200 indications in more than 20 therapeutic areas. To meet the evolving demands of clinical research, Kayentis offers a comprehensive suite of services that prioritize scientific integrity and patient-centric approaches. With operational capabilities spanning the USA, Europe, and Asia, the company's technology facilitates electronic data capture, providing a versatile range of tools designed to simplify data collection for both patients and clinical trial sites.

Previa Medical is a health technology company that focuses on analyzing patient data in real-time to identify risks of complications and provide predictive insights. Utilizing FHIR technology, the company's platform integrates with existing hospital software, accessing electronic health records (EHR), laboratory results, vital signs, and medical history. This comprehensive data analysis enables healthcare professionals to promptly identify at-risk patients and deliver necessary treatments, ultimately enhancing patient survival rates. Previa Medical's solutions aim to improve the efficiency and effectiveness of healthcare delivery by leveraging advanced data analytics.

Previa Medical is a health technology company that focuses on analyzing patient data in real-time to identify risks of complications and provide predictive insights. Utilizing FHIR technology, the company's platform integrates with existing hospital software, accessing electronic health records (EHR), laboratory results, vital signs, and medical history. This comprehensive data analysis enables healthcare professionals to promptly identify at-risk patients and deliver necessary treatments, ultimately enhancing patient survival rates. Previa Medical's solutions aim to improve the efficiency and effectiveness of healthcare delivery by leveraging advanced data analytics.

Dianosic SAS, founded in 2017 and based in Strasbourg, France, specializes in developing advanced medical devices for Ear, Nose, and Throat (ENT) conditions. The company has created CAVI-T, an innovative intranasal balloon designed to stop spontaneous or postoperative bleeding through low-pressure compression, while also preventing biofilm formation and enhancing healing. Additionally, Dianosic is working on the Active Resorbable Intranasal Scaffold (ARIS), a groundbreaking treatment for chronic sinusitis and allergic rhinitis, which offers a long-lasting drug-eluting solution that can last from six to twelve months. This technology not only addresses patient compliance challenges but also presents opportunities for expanding treatment options in related areas such as chronic migraine and facial pain. Through its cutting-edge solutions, Dianosic aims to redefine standards of care in ENT healthcare.

Orthopus manufactures and distributes medical devices. They develop a range of robotic devices for arm mobility. Their supporter compensates for the weight of the arm to facilitate vertical movements. Their robotic device is used in an electric wheelchair and on a table.

Oneleaf is a startup focused on making hypnosis more accessible to individuals seeking personal improvement. The company has developed a self-hypnosis app that offers various programs aimed at addressing issues such as smoking cessation, anxiety reduction, and weight loss. By providing expert-guided digital resources, Oneleaf aims to assist users in overcoming detrimental habits and enhancing their overall well-being. The overarching goal of the company is to empower a billion people to achieve their best selves through self-hypnosis.

WeLinQ is an online platform that provides free consultation services and easy messaging with therapists. They provide a practical substitute for in-person therapy with advantages including anytime messaging, adaptable scheduling, simple therapist switching, and the capacity to take part in sessions from any location.

Elis is a multi-services group operating in Europe and Brazil, specializing in the rental and maintenance of professional clothing, flat linen, and hygiene appliances. The company provides a wide range of tailored solutions, including services for washrooms, floor protection, beverages, cleanrooms, pest control, and medical waste management. With over 19,000 employees across 13 countries, Elis serves more than 240,000 businesses in various sectors, including hospitality, healthcare, industry, retail, and services. The company's extensive network of nearly 300 production and distribution centers, alongside 13 clean rooms, enables it to maintain strong proximity to its clients and deliver high-quality services efficiently. With over a century of experience, Elis has established itself as a leader in cleanliness, image, hygiene, and well-being services.

ErVaccine Technologies creates immunotherapies that integrate T-cell treatments with cancer vaccinations to meet a medical need for cold tumors. They are committed to identifying tumor epitopes that are physician. They come from endogenous retroviruses and are novel cancer epitopes. They use a bioinformatics-based strategy to find possible epitopes, which are then verified by proteomics and immunological testing.

Ganymed Robotics SAS is a medical device company based in Paris, France, established in 2018. The company specializes in developing advanced robotics technologies and software aimed at enhancing surgical precision in orthopedic procedures, particularly focusing on knee replacement surgeries. Its innovative therapeutic device is designed to improve patient outcomes and streamline the surgical process, enabling orthopedic surgeons to reduce operating times and enhance their overall experience. By integrating robotics into surgical practices, Ganymed Robotics aims to advance the efficiency of care delivery in the orthopedic field.

Clarity is a clinical-stage company pioneering a new category of non-pharmacological treatments for neurodegenerative diseases. We develop a neuromodulation device combining immersive technology, AI and biosensors to deliver gamma sensory stimulation. Gamma waves’ sensory stimulation has been shown to significantly slow down Alzheimer's progression, reducing neurodegeneration and cognitive decline. Clarity takes a platform approach by enabling the customization of sensory stimulation protocols based on patient data, improving experience, efficacy and scalability across a wide range of indications. The company was founded by neuroscientists from UC Berkeley, and Oxford along with execs from OURA and Philips, and is supported by leading institutions such as UCSF's Neuroscape.

Remedee Labs SAS is a French company founded in 2016, specializing in the research and development of a personal endorphin stimulator aimed at pain management. The company has created the Microelectronic Endorphin Trigger (MEET), a device designed to stimulate the release of the body’s own endorphins on demand. This innovative technology is particularly focused on helping individuals suffering from chronic pain conditions, with an initial emphasis on fibromyalgia. Remedee Labs has developed a patient-centered digital service platform that collaborates with medical practitioners to enhance chronic pain management. Backed by a decade of pre-clinical and clinical research, the company aims to provide a new approach to pain relief for the 1.5 billion people worldwide affected by chronic pain, many of whom are dissatisfied with existing treatment options. In 2019, Remedee Labs secured significant funding from various investors to further its mission of making endorphin-stimulation therapy accessible and effective for personal healthcare.

Microphyt specializes in the research, development, production, and marketing of natural algae-based products aimed at enhancing health and wellness. The company focuses on creating bioactive dietary supplements that support weight loss and brain health. Utilizing an industrial-scale supply of microalgae biomass and extracts, Microphyt ensures the preservation of cell integrity while producing commercial quantities of slow-growing or biofilm-forming species. This approach enables the healthcare industry to effectively meet the demands of personal care and food products, positioning Microphyt as a key player in the market for natural health solutions.

Jalon Therapeutics is focused on developing innovative therapies that target essential tumor signaling pathways that have not yet been addressed. The company aims to transform the lives of cancer patients by creating medicines that effectively inhibit these pathways. Through its research, Jalon Therapeutics explores the potential of non-oncogene addiction to discover new therapeutic targets and develop groundbreaking anticancer treatment strategies. The company's work is centered on improving treatment options for individuals battling cancer, ultimately striving to enhance their quality of life.

Meccellis Biotech SAS, founded in 2013 and based in La Rochelle, France, specializes in developing biologic implants using acellular dermis. The company focuses on tissue and cell engineering to create biological implants that facilitate tissue repair across various surgical specialties. Their product offerings include Cellis and Cellis breast implants, designed to address specific clinical needs during surgical procedures, such as abdominal wall repair. By maintaining continuous communication with surgeons, Meccellis Biotech aims to provide tailored solutions that meet the evolving demands of the medical field.

Livmed's is a software platform based in Nice, France, that specializes in home medicine delivery services. Founded in 2020, the company facilitates the delivery of both prescription and non-prescription medications directly to individuals from local drugstores. The platform operates around the clock, ensuring convenient access to healthcare and enabling users to receive their medications without the need for an in-person visit to a pharmacy. Through its services, Livmed's aims to enhance the accessibility of medicines for citizens and healthcare providers alike.

Lys Therapeutics is a biotechnology company focused on developing therapies for patients with neurovascular and neurodegenerative disorders. The company is centered around its lead product, Glunozumab, a monoclonal antibody that operates through a unique mechanism of action. This drug induces off-target toxicity by hyperactivating vascular and neuronal NMDA receptors, which can lead to significant disruptions in the blood-brain and blood-spinal cord barriers, as well as neuronal excitotoxicity. These effects are particularly relevant in conditions such as stroke and multiple sclerosis, where the modulation of neuroinflammation is critical for treatment.

Lola Health is an insurance technology firm that provides personalized health coverage tailored to the needs of its clients' businesses. The company focuses on enhancing employee well-being by offering support for various health issues, including female health, alternative medicine, and mental health. Lola Health's services include Angel Plus, an advisory platform that assists employees in navigating their health care options, as well as telecommunications and psychological support. By modernizing traditional insurance models, Lola Health aims to offer comprehensive coverage that includes assistance for care pathways like endometriosis, parenthood, and postpartum depression. This approach not only helps businesses attract and retain talent but also promotes overall employee performance and wellness.

Incepto Medical SAS, established in 2018 and headquartered in Paris, France, specializes in developing and distributing artificial intelligence (AI) applications for medical imaging. The company's portfolio includes software solutions like Qure.ai qER for head CT analysis, Qure.ai qXR for thorax abnormality detection, Aidence Veye Chest for pulmonary nodule tracking, Icometric Icobrain for neurological disorder monitoring, and ScreenPoint Transpara for breast cancer detection. Additionally, Incepto operates Collective Minds Radiology, an online platform facilitating case support, opinion sharing, and learning among healthcare professionals. The company aims to empower healthcare professionals by providing AI-driven tools that help manage the increasing volume of patients and images, ultimately enhancing patient care.

Tridek-One is a biotechnology company focused on developing immunomodulatory products aimed at treating autoimmune diseases and inflammatory disorders. The company has created a peptide that preserves a cluster of truncated CD31 molecules at the membrane, allowing for the moderation of overactive immune responses without complete blockade. This innovative approach enables medical companies to provide enhanced therapeutic options, ultimately improving patient outcomes and quality of life.

SparingVision SAS is a biotechnology company based in Paris, France, dedicated to discovering and developing gene therapy-based treatments for inherited retinal diseases that can lead to blindness. Founded in 2016, the company is focused on creating innovative therapies for conditions such as retinitis pigmentosa, the most prevalent form of inherited retinal degeneration, which currently lacks comprehensive treatment options. SparingVision is advancing its lead candidate, SPVN06, which aims to address the needs of the nearly 2 million individuals affected by this rare genetic disorder globally. By targeting the underlying causes of these diseases, SparingVision seeks to improve the quality of life for patients suffering from genetic retinal disorders.

Cuure specializes in providing personalized vitamins and supplements tailored to individual health requirements. Utilizing data from health questionnaires and DNA tests, Cuure develops customized supplement plans aimed at enhancing overall health and wellness. Their offerings combine scientific research with a personalized approach, ensuring that users receive recommendations aligned with their specific health goals and body chemistry. Additionally, the platform promotes wellness habits through a tracking application, allowing individuals to monitor their supplement intake and adapt their health practices effectively. Cuure's commitment to fair pricing and personalized solutions makes it a distinctive player in the wellness industry.

DeepLife is a biotech company based in Paris, France, founded in 2019. It focuses on developing digital twins of cells to enhance drug discovery processes. By utilizing deep learning techniques on multi-omics data, DeepLife models cellular behavior and simulates responses to various genetic screenings, such as siRNA and CRISPR-Cas9. This approach allows the identification of new drug targets, biomarkers, and potential drug candidates, enabling a better understanding of drug resistance and sensitivity. The company's mission is to advance systems biology and facilitate the transition of laboratory discoveries to clinical applications. DeepLife collaborates with academic institutions to leverage expertise and drive innovation in the biopharmaceutical industry, ultimately aiming to match the right drug to the right patient.

Chipiron is a developer of innovative portable MRI machines that utilize advanced quantum detectors to generate three-dimensional anatomical images. By operating at ultra-low magnetic fields, these machines are designed to be lightweight and efficient, significantly reducing costs compared to traditional MRI technologies. The company's focus on employing quantum sensors enhances the capability of these portable devices for disease detection, diagnosis, and treatment monitoring, particularly for brain-related conditions. This approach aims to empower healthcare institutions to improve patient outcomes and decrease the fatality rates associated with neurological diseases.

Qairn specializes in digitizing regulatory processes for healthcare manufacturers, including laboratories, medical devices, and biotechs. The company offers a SaaS platform that streamlines and secures mandatory procedures, facilitating the management of promotional materials and other regulated content. Qairn's services include the review and validation of promotional documents, submission to ANSM, and compliance support, allowing clients to efficiently navigate regulatory requirements while minimizing risks. By simplifying these processes, Qairn enables its clients to focus on innovation and improving healthcare outcomes.

Ludocare focuses on developing therapeutic robots that assist patients with chronic diseases and their families. The company's innovative devices are designed to complement traditional drug treatments by providing personalized support that enhances treatment efficiency. By empowering patients, especially children, Ludocare aims to improve therapeutic compliance both quantitatively and qualitatively. This approach facilitates better disease management and helps stabilize essential treatments, ultimately contributing to improved autonomy and quality of life for patients and their families.

SPART supports companies in the process of improving quality of life at work by offering solutions to activate health and well-being practices each day in a professional environment. They are partners for corporate sporting challenges. They enable everyone to achieve their full potential through innovative physical activities within the company.

Sonio is an AI-based support platform for fetal ultrasound, helping practitioners analyze and diagnose congenital malformations. Sonio combines the patient’s medical history, genetic and biological data, and ultrasound semiology to assist physicians on the path to the right diagnosis. It assists sonographers during prenatal screening scans, helping them ensure that they have not forgotten anything, take risk factors into account, and facilitate the sharing of images with patients and other health professionals.

Nurea develops a decision-making support solution specifically for healthcare professionals, particularly vascular surgeons. The company specializes in medical imaging software that automates image analysis, providing accurate quantitative assessments to aid in the diagnosis of vascular diseases. Its platform facilitates the management of patient groups during both pre- and post-operative monitoring through an automated workflow, which includes comprehensive full-body scan analysis. By offering decision indicators aimed at preventing cardiovascular incidents, Nurea simplifies the decision-making process for surgeons, enhancing patient care in the realm of cardiovascular health. An online inquiry form is available on their website for further information.

Healshape is a biotech startup dedicated to developing natural breast reconstruction solutions for women. The company specializes in regenerative medicine, focusing on creating innovative alternatives for breast regeneration through advanced 3D bioprinting technology. Healshape's primary product is a bioprosthesis designed for breast reconstruction, which aims to empower women by helping them regain self-confidence and achieve long-lasting, aesthetically pleasing results following surgery.

Diabeloop is a medical device company based in Grenoble, France, focused on innovating diabetes treatment through advanced technology. Founded in 2015, the company specializes in developing an AI-based closed-loop system that automates insulin delivery for individuals with type 1 diabetes. This system includes a blood sugar monitoring device that combines a glucose sensor, an insulin pump, and a smartphone application featuring an embedded algorithm. By continuously measuring glucose levels and delivering the appropriate insulin dosage, Diabeloop aims to reduce the mental burden on patients, allowing them to manage their condition more effectively and live their lives with greater ease.

Implicity is a developer of a remote monitoring platform that specializes in the smart monitoring of patients with connected cardiac devices, such as pacemakers and defibrillators. The platform utilizes artificial intelligence to sort and summarize patient data, assessing the criticality of alerts based on individual medical contexts. This capability allows cardiologists and healthcare professionals to automate the monitoring process, enabling them to effectively oversee patient health while consolidating information on a single platform. By streamlining remote monitoring, Implicity aims to enhance the quality of care provided to patients with cardiac implants.

Hemerion is a biotechnology company dedicated to developing innovative cancer treatments, specifically targeting glioblastoma, the most prevalent and aggressive primary brain tumor. The company operates a platform that integrates therapeutic services at the intersection of surgery and photonics, utilizing a photosensitizing drug for a drug-device combination therapy. This approach enables healthcare professionals to selectively destroy cancer cells in regions that are difficult to access through traditional surgical methods, all while preserving healthy tissues. Hemerion's focus on advanced treatment options aims to enhance the healthcare industry's ability to combat brain cancer and improve patient outcomes in the fight against glioblastoma.

Ribonexus is a biotechnology company dedicated to developing innovative therapies aimed at treating cancer, particularly melanoma. The company is focused on creating a pipeline of small molecules that target the eukaryotic translation Initiation Factor-4A (eIF4A), which plays a significant role in various solid and hematologic cancers. This target is particularly relevant for addressing resistance to existing treatments, which often diminishes the effectiveness of targeted therapies. Ribonexus aims to produce drugs that can restore sensitivity to these therapies in patients who have developed resistance, thereby improving treatment outcomes in oncology.

Ribonexus is a biotechnology company dedicated to developing innovative therapies aimed at treating cancer, particularly melanoma. The company is focused on creating a pipeline of small molecules that target the eukaryotic translation Initiation Factor-4A (eIF4A), which plays a significant role in various solid and hematologic cancers. This target is particularly relevant for addressing resistance to existing treatments, which often diminishes the effectiveness of targeted therapies. Ribonexus aims to produce drugs that can restore sensitivity to these therapies in patients who have developed resistance, thereby improving treatment outcomes in oncology.

Guard Medical is a medical device company that specializes in developing innovative solutions for wound care. Its primary product, NPseal™, is designed for prophylactic negative pressure wound therapy (NPWT) of closed surgical incisions. This device aims to reduce surgical site infections and improve the healing process by establishing and maintaining negative pressure with minimal effort. By integrating an easy-to-use pump, NPseal™ allows patients to effectively prevent infection and minimize scarring, ultimately enhancing the cosmetic outcomes of surgical wounds. The company focuses on creating cost-effective alternatives that prioritize patient care and recovery.

LimFlow is a developer of innovative peripheral endovascular technology aimed at treating end-stage chronic limb ischemia (CLI) patients. The LimFlow System uses a novel, ultrasound-guided percutaneous procedure to divert blood around diseased arteries into the tibial vein, effectively supplying oxygenated blood to the ischemic foot. This approach offers new hope to patients who have exhausted other revascularization options. By restoring blood flow, the system alleviates ischemic pain, promotes wound healing, reduces the risk of amputations, and helps restore mobility. Currently, the LimFlow System is approved for sale in markets regulated by the CE Mark, while in the United States, it remains an investigational device limited to research use.